title: Refractory multiple myeloma treated with homoharringtonine: report of two cases.
authors.forename: Xiudi
authors.initials: X
authors.lastname: Yang
authors.forename: Chunmei
authors.initials: C
authors.lastname: Yang
authors.forename: Keding
authors.initials: K
authors.lastname: Shao
authors.forename: Xingnong
authors.initials: X
authors.lastname: Ye
authors.forename: Haitao
authors.initials: H
authors.lastname: Meng
authors.forename: Yuhong
authors.initials: Y
authors.lastname: Zhou
authors.forename: Wenbin
authors.initials: W
authors.lastname: Qian
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006248:Harringtonines / Q000008:administration & dosage*; D000077863:Homoharringtonine; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy*; D010087:Oxides / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D016879:Salvage Therapy; D013792:Thalidomide / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D001152:Arsenicals; D006248:Harringtonines; D010087:Oxides; D013792:Thalidomide; D014750:Vincristine; D000077863:Homoharringtonine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D014751:Vindesine; D000077237:Arsenic Trioxide; D002330:Carmustine; D011241:Prednisone